HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Farm Bill Hemp Provision Lights Another Supplement Industry Regulatory Priority

Executive Summary

Bills proposing changes the supplement industry prioritized during Congress' 2017-18 session weren't written by Sen. McConnell, or other Republican leadership members, unlike hemp provision passed as part of farm bill. "When the majority leader of the Senate puts his weight behind legislation on behalf of his constituency, that makes a big difference," says Mike Greene, Council for Responsible Nutrition's government affairs chief.

You may also be interested in...

Complicated Regulatory Odyssey Steers FDA Toward Rule On CBD In Supplements

Before Congress de-scheduled hemp at end of 2018 and forced agency's hand on considering lawful use of ingredients derived from the plant in supplements and food, the floodgate for sales of the products was opened in 2013 by a DoJ policy change to de-emphasize enforcement of most federal marijuana laws.

CBD Market Survival-Of-Fittest Looms With FDA Regulation, Industry Standards

Number of hemp and CBD supplement marketers will shrink as passage of farm bill leads to industry certification as well as FDA enforcement. Firms practicing transparency are most likely to survive in a few years.

CBD On OTC Industry Radar As Regulatory Questions Cloud Runway

With US market of hemp- and CBD-containing supplements and food booming, likelihood is growing products made with ingredients will gain approval in the country to be marketed with consumer health indications, said consumer health business executives during a panel discussion at CHPA conference. Legalization of marijuana sales and use by some states and other countries also will influence future of CBD use in US consumer health products, they say.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts